Harvey Rosenstock
Bellaire, TXNPI 1043211972
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,310 of the $32,842 with a category attached, or 77.1%. AbbVie accounts for 85.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $10,635 and has fallen 93.4% since, to $698 in 2024.
Across 353 payments — averaging $93.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Bausch Health US, LLC$1K
- Otsuka America Pharmaceutical, Inc.$664
- Lundbeck LLC$526
- Vanda Pharmaceuticals Inc.$525
- Takeda Pharmaceuticals U.S.A., Inc.$462
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$25,31077%
- Travel & lodging$1,8516%
- Food & beverage$5,67517%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $28,217 |
| Bausch Health US, LLC | 92 | $1,144 |
| Otsuka America Pharmaceutical, Inc. | 25 | $664 |
| Lundbeck LLC | 26 | $526 |
| Vanda Pharmaceuticals Inc. | 30 | $525 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $462 |
| Neurocrine Biosciences, Inc. | 5 | $226 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $215 |
| Sunovion Pharmaceuticals Inc. | 15 | $161 |
| Corium, LLC | 12 | $155 |
| Eisai Inc. | 9 | $127 |
| Ironshore Pharmaceuticals Inc. | 6 | $110 |
| Shire North American Group Inc | 5 | $89 |
| Alkermes, Inc. | 3 | $72 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate ErQuetiapine Fumarate | 24 | $1,501 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $834 |
| Alprazolam | 43 | $414 |
| Quetiapine Fumarate | 23 | $408 |
| Bupropion XlBupropion Hcl | 17 | $190 |
| Clonazepam | 34 | $140 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.